Weight loss medications may lead to hair loss, according to recent research findings. A study involving 50,000 individuals using weight loss injections like Wegovy and Mounjaro has indicated a potential connection with a rare side effect known as alopecia.
Reports of hair loss from individuals taking appetite-suppressing medications have been submitted to regulatory bodies, raising concerns about the drugs’ role in this issue. Analyzing electronic patient data from the University of Pennsylvania Health System in the US revealed a possible association between weight loss drugs and hair loss.
Comparing patients on weight loss medications to those on different diabetes treatments, the study published in the British Medical Journal showed a 68% higher likelihood of hair loss among the former group. Experts suggest that this hair loss could be attributed to sudden decreases in calorie intake and deficiencies in essential nutrients.
Dr. Yong Chen from the University of Pennsylvania highlighted that changes in weight and nutrition are known triggers for telogen effluvium, a type of non-scarring hair loss. While hair loss may not pose physical harm, it can significantly impact self-esteem, quality of life, and treatment adherence.
The study linked weight loss medications to non-scarring alopecia, leaving room for potential hair regrowth. Weekly injections like Ozempic, Wegovy, and Mounjaro function by slowing digestion and reducing appetite through mimicking a hormone called glucagon-like peptide 1 (GLP-1), responsible for regulating hunger and fullness.
In light of these findings, experts, including Dr. Amir Khan, have advocated for alternative weight loss methods. Researchers focused on individuals with type 2 diabetes taking GLP-1 drugs, SGLT-2 inhibitors, and DPP-4 inhibitors, finding a higher risk of alopecia associated with GLP-1 medications.
Dr. Marie Spreckley from Cambridge University emphasized that rapid weight loss and nutritional deficiencies could contribute to temporary hair shedding. While acknowledging the potential adverse effects of GLP-1 drugs, she underscored the established benefits in managing blood sugar levels, reducing weight, and lowering obesity-related risks.
Besides hair loss, common side effects of GLP-1 drugs include vomiting and constipation, necessitating personalized support for weight maintenance. While the NHS prescribes Mounjaro and Wegovy for weight loss and Ozempic for diabetes, patients should be aware of these potential effects and benefits when considering treatment options.
